Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomedical Research | 4 | 2023 | 467 | 1.330 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 728 | 0.820 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2020 | 85 | 0.530 |
Why?
|
| Myopia | 8 | 2005 | 29 | 0.480 |
Why?
|
| Georgia | 8 | 2024 | 189 | 0.480 |
Why?
|
| Humans | 56 | 2024 | 42113 | 0.390 |
Why?
|
| Female | 39 | 2024 | 23980 | 0.350 |
Why?
|
| Eyeglasses | 7 | 2005 | 23 | 0.350 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2003 | 82 | 0.340 |
Why?
|
| Visual Acuity | 8 | 2015 | 117 | 0.310 |
Why?
|
| Male | 36 | 2024 | 22745 | 0.290 |
Why?
|
| Residence Characteristics | 3 | 2021 | 358 | 0.290 |
Why?
|
| Resilience, Psychological | 2 | 2020 | 89 | 0.290 |
Why?
|
| Adult | 20 | 2024 | 13437 | 0.280 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2008 | 41 | 0.280 |
Why?
|
| Mentors | 3 | 2023 | 143 | 0.270 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 229 | 0.260 |
Why?
|
| Patient Compliance | 1 | 2008 | 225 | 0.250 |
Why?
|
| Health Status Disparities | 3 | 2024 | 702 | 0.240 |
Why?
|
| Middle Aged | 18 | 2023 | 11790 | 0.230 |
Why?
|
| Receptors, KIR | 2 | 2015 | 5 | 0.230 |
Why?
|
| Thyroidectomy | 2 | 2014 | 10 | 0.220 |
Why?
|
| Risk Assessment | 4 | 2020 | 844 | 0.220 |
Why?
|
| Glucocorticoids | 2 | 2015 | 92 | 0.220 |
Why?
|
| Aged | 14 | 2023 | 7958 | 0.210 |
Why?
|
| Killer Cells, Natural | 2 | 2015 | 99 | 0.210 |
Why?
|
| Disease Progression | 9 | 2008 | 660 | 0.210 |
Why?
|
| Intraocular Pressure | 4 | 2003 | 133 | 0.210 |
Why?
|
| Fathers | 1 | 2024 | 35 | 0.210 |
Why?
|
| Child | 15 | 2020 | 3381 | 0.210 |
Why?
|
| Vision Tests | 1 | 2003 | 6 | 0.200 |
Why?
|
| Adolescent | 9 | 2023 | 5949 | 0.200 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 2790 | 0.200 |
Why?
|
| Internet | 1 | 2024 | 234 | 0.200 |
Why?
|
| Breast Feeding | 1 | 2024 | 123 | 0.190 |
Why?
|
| Haplotypes | 2 | 2020 | 197 | 0.180 |
Why?
|
| Tropicamide | 1 | 2001 | 1 | 0.180 |
Why?
|
| Body Mass Index | 4 | 2021 | 915 | 0.180 |
Why?
|
| Pupil | 1 | 2001 | 9 | 0.180 |
Why?
|
| Mydriatics | 1 | 2001 | 6 | 0.180 |
Why?
|
| Young Adult | 6 | 2024 | 4928 | 0.180 |
Why?
|
| Diploidy | 2 | 2020 | 6 | 0.170 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2021 | 93 | 0.170 |
Why?
|
| Double-Blind Method | 7 | 2014 | 305 | 0.160 |
Why?
|
| Lactobacillus acidophilus | 2 | 2010 | 3 | 0.160 |
Why?
|
| Urban Health | 1 | 2020 | 99 | 0.160 |
Why?
|
| Students, Medical | 1 | 2021 | 153 | 0.150 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 137 | 0.150 |
Why?
|
| Risk Factors | 9 | 2021 | 3933 | 0.150 |
Why?
|
| Probiotics | 2 | 2010 | 37 | 0.150 |
Why?
|
| Convergence, Ocular | 2 | 1999 | 3 | 0.150 |
Why?
|
| Betaxolol | 3 | 2003 | 3 | 0.150 |
Why?
|
| United States | 4 | 2023 | 5068 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 727 | 0.150 |
Why?
|
| Trabeculectomy | 3 | 2003 | 32 | 0.140 |
Why?
|
| Accommodation, Ocular | 5 | 2004 | 6 | 0.140 |
Why?
|
| Awareness | 1 | 2018 | 73 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2019 | 158 | 0.140 |
Why?
|
| Parathyroid Hormone | 2 | 2014 | 40 | 0.140 |
Why?
|
| Intention | 1 | 2018 | 103 | 0.140 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 163 | 0.130 |
Why?
|
| Mortality | 1 | 2019 | 174 | 0.130 |
Why?
|
| Registries | 2 | 2019 | 430 | 0.130 |
Why?
|
| Social Class | 1 | 2019 | 286 | 0.130 |
Why?
|
| Medicare | 1 | 2019 | 325 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2019 | 335 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2003 | 54 | 0.120 |
Why?
|
| Papillomavirus Vaccines | 1 | 2018 | 168 | 0.120 |
Why?
|
| Macular Edema | 1 | 2015 | 5 | 0.120 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 1051 | 0.120 |
Why?
|
| Dexamethasone | 1 | 2015 | 55 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 570 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 62 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2015 | 1582 | 0.110 |
Why?
|
| Lipids | 1 | 2016 | 256 | 0.110 |
Why?
|
| Hypoparathyroidism | 1 | 2014 | 2 | 0.110 |
Why?
|
| Cerebral Ventricles | 1 | 2014 | 23 | 0.110 |
Why?
|
| Hydrocephalus | 1 | 2014 | 16 | 0.110 |
Why?
|
| Granisetron | 1 | 2014 | 1 | 0.110 |
Why?
|
| Antiemetics | 1 | 2014 | 8 | 0.110 |
Why?
|
| Hypocalcemia | 1 | 2014 | 4 | 0.110 |
Why?
|
| Vomiting | 1 | 2014 | 14 | 0.110 |
Why?
|
| Gastroenteritis | 1 | 2014 | 18 | 0.110 |
Why?
|
| Prednisolone | 1 | 2014 | 16 | 0.110 |
Why?
|
| Budesonide | 1 | 2014 | 5 | 0.110 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 77 | 0.110 |
Why?
|
| Bronchodilator Agents | 1 | 2014 | 26 | 0.110 |
Why?
|
| HIV Infections | 1 | 2008 | 2535 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 363 | 0.110 |
Why?
|
| Eye | 2 | 2005 | 80 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2019 | 1570 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 3 | 0.100 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2013 | 17 | 0.100 |
Why?
|
| Sexual Behavior | 1 | 2018 | 634 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 104 | 0.100 |
Why?
|
| Prognosis | 5 | 2020 | 847 | 0.100 |
Why?
|
| Saudi Arabia | 3 | 2020 | 7 | 0.100 |
Why?
|
| Visual Fields | 1 | 2003 | 75 | 0.100 |
Why?
|
| Vision Disorders | 1 | 2003 | 61 | 0.100 |
Why?
|
| Parents | 1 | 2016 | 359 | 0.090 |
Why?
|
| Refraction, Ocular | 5 | 2005 | 66 | 0.090 |
Why?
|
| Vitamin D | 1 | 2014 | 196 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2021 | 2466 | 0.090 |
Why?
|
| Sex Factors | 5 | 2014 | 1004 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1265 | 0.090 |
Why?
|
| Hunger | 1 | 2011 | 12 | 0.090 |
Why?
|
| Calcium | 1 | 2014 | 487 | 0.090 |
Why?
|
| Aging | 1 | 2016 | 763 | 0.090 |
Why?
|
| Dietary Fiber | 1 | 2011 | 50 | 0.090 |
Why?
|
| Gene Expression | 1 | 2014 | 692 | 0.080 |
Why?
|
| Strabismus | 2 | 2004 | 17 | 0.080 |
Why?
|
| Vitreous Body | 2 | 2015 | 11 | 0.080 |
Why?
|
| Energy Intake | 1 | 2011 | 162 | 0.080 |
Why?
|
| Body Composition | 1 | 2011 | 160 | 0.080 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 8 | 0.080 |
Why?
|
| Asthma | 1 | 2014 | 410 | 0.080 |
Why?
|
| Exotropia | 1 | 1999 | 3 | 0.080 |
Why?
|
| Bifidobacterium | 1 | 2009 | 4 | 0.080 |
Why?
|
| Common Cold | 1 | 2009 | 5 | 0.080 |
Why?
|
| Child, Preschool | 4 | 2016 | 1515 | 0.080 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 1999 | 7 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2011 | 208 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2010 | 415 | 0.080 |
Why?
|
| Diarrhea | 1 | 2010 | 95 | 0.080 |
Why?
|
| Body Weight | 1 | 2011 | 428 | 0.080 |
Why?
|
| Overweight | 1 | 2011 | 248 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2009 | 90 | 0.070 |
Why?
|
| Hospitals, Special | 1 | 1998 | 3 | 0.070 |
Why?
|
| Optometry | 1 | 1998 | 5 | 0.070 |
Why?
|
| Prevalence | 3 | 2020 | 1593 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2008 | 123 | 0.070 |
Why?
|
| Ophthalmic Solutions | 2 | 2003 | 18 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 209 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2021 | 658 | 0.070 |
Why?
|
| Age Factors | 3 | 2009 | 1135 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 704 | 0.060 |
Why?
|
| Health Care Costs | 1 | 1996 | 89 | 0.060 |
Why?
|
| Fraud | 1 | 2024 | 9 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 1994 | 10 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2015 | 53 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 233 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 13 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 1995 | 81 | 0.050 |
Why?
|
| Anterior Chamber | 1 | 2004 | 14 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 3073 | 0.050 |
Why?
|
| Soft Tissue Neoplasms | 2 | 1993 | 15 | 0.050 |
Why?
|
| Lens, Crystalline | 1 | 2004 | 46 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 437 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2004 | 1058 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 1993 | 92 | 0.050 |
Why?
|
| Laser Therapy | 2 | 2003 | 25 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2024 | 208 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 512 | 0.050 |
Why?
|
| Capacity Building | 1 | 2023 | 99 | 0.050 |
Why?
|
| Focus Groups | 1 | 2024 | 398 | 0.050 |
Why?
|
| Physical Examination | 1 | 2021 | 45 | 0.040 |
Why?
|
| American Heart Association | 1 | 2021 | 21 | 0.040 |
Why?
|
| Eye Color | 1 | 2001 | 3 | 0.040 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 41 | 0.040 |
Why?
|
| Censuses | 1 | 2021 | 28 | 0.040 |
Why?
|
| Technology | 1 | 2021 | 28 | 0.040 |
Why?
|
| Adenosine | 1 | 2020 | 62 | 0.040 |
Why?
|
| Health Education | 1 | 2024 | 358 | 0.040 |
Why?
|
| Learning | 1 | 2021 | 155 | 0.040 |
Why?
|
| Community-Based Participatory Research | 1 | 2024 | 336 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2020 | 65 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 1996 | 1679 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2021 | 386 | 0.040 |
Why?
|
| Curriculum | 1 | 2021 | 311 | 0.040 |
Why?
|
| Cities | 1 | 2019 | 78 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 135 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1733 | 0.040 |
Why?
|
| Life Style | 1 | 2020 | 326 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 370 | 0.030 |
Why?
|
| Diet | 1 | 2024 | 810 | 0.030 |
Why?
|
| Minority Groups | 1 | 2023 | 663 | 0.030 |
Why?
|
| Physicians | 1 | 2019 | 180 | 0.030 |
Why?
|
| Health Status | 1 | 2020 | 432 | 0.030 |
Why?
|
| Florida | 1 | 2018 | 461 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 73 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 99 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1001 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 2015 | 11 | 0.030 |
Why?
|
| Health Behavior | 1 | 2020 | 568 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1221 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2015 | 85 | 0.030 |
Why?
|
| Drug Implants | 1 | 2015 | 20 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 674 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 1993 | 411 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 42 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 118 | 0.030 |
Why?
|
| Universities | 1 | 2018 | 539 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 9 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 33 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 200 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 2014 | 7 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2014 | 28 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 180 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 31 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2014 | 22 | 0.030 |
Why?
|
| Arabs | 1 | 2014 | 19 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 1993 | 3 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 1993 | 8 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 156 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 203 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2014 | 127 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 256 | 0.030 |
Why?
|
| Survival Analysis | 2 | 1995 | 362 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1019 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 116 | 0.020 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1993 | 3 | 0.020 |
Why?
|
| Lectins | 1 | 1993 | 19 | 0.020 |
Why?
|
| Sarcoma | 1 | 1993 | 11 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1993 | 11 | 0.020 |
Why?
|
| Lactones | 1 | 1993 | 22 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 959 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 792 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 107 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 351 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 574 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2014 | 1728 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 174 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2014 | 253 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 84 | 0.020 |
Why?
|
| Carcinoma | 1 | 2013 | 106 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 268 | 0.020 |
Why?
|
| Polysaccharides | 1 | 2011 | 70 | 0.020 |
Why?
|
| Infant | 1 | 2014 | 1142 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 285 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 41 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 1845 | 0.020 |
Why?
|
| Philadelphia | 1 | 1999 | 20 | 0.020 |
Why?
|
| Chicago | 1 | 1999 | 30 | 0.020 |
Why?
|
| Regression Analysis | 2 | 1996 | 487 | 0.020 |
Why?
|
| Absenteeism | 1 | 2009 | 14 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 236 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 34 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 531 | 0.020 |
Why?
|
| New York | 1 | 1998 | 88 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 584 | 0.020 |
Why?
|
| California | 1 | 1999 | 531 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 744 | 0.020 |
Why?
|
| Urban Population | 1 | 1999 | 364 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1111 | 0.020 |
Why?
|
| Relative Value Scales | 1 | 1996 | 1 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2005 | 25 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1995 | 53 | 0.010 |
Why?
|
| Incidence | 1 | 1998 | 1052 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1996 | 366 | 0.010 |
Why?
|
| Work | 1 | 2004 | 7 | 0.010 |
Why?
|
| Reading | 1 | 2004 | 13 | 0.010 |
Why?
|
| Cisplatin | 1 | 1995 | 91 | 0.010 |
Why?
|
| Lomustine | 1 | 1994 | 1 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1994 | 6 | 0.010 |
Why?
|
| Prednisone | 1 | 1994 | 31 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1994 | 53 | 0.010 |
Why?
|
| Bleomycin | 1 | 1994 | 21 | 0.010 |
Why?
|
| Biometry | 1 | 2004 | 50 | 0.010 |
Why?
|
| Anthropometry | 1 | 2004 | 96 | 0.010 |
Why?
|
| Recurrence | 1 | 1994 | 149 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 132 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1994 | 95 | 0.010 |
Why?
|
| Prescriptions | 1 | 2003 | 19 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1995 | 357 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 224 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 249 | 0.010 |
Why?
|
| Cornea | 1 | 2002 | 81 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2001 | 55 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1993 | 24 | 0.010 |
Why?
|
| Pepsin A | 1 | 1993 | 4 | 0.010 |
Why?
|
| Pronase | 1 | 1993 | 4 | 0.010 |
Why?
|
| Bryostatins | 1 | 1993 | 3 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1993 | 4 | 0.010 |
Why?
|
| Ploidies | 1 | 1993 | 7 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1993 | 23 | 0.010 |
Why?
|
| Trypsin | 1 | 1993 | 40 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1993 | 13 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 42 | 0.010 |
Why?
|
| Macrolides | 1 | 1993 | 14 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1993 | 57 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1993 | 30 | 0.010 |
Why?
|
| Cell Count | 1 | 1993 | 140 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1993 | 122 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1993 | 124 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1993 | 462 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 506 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1993 | 633 | 0.000 |
Why?
|